Colgate Palmolive Company (CL) reported results for the third quarter of 2009 with earnings of $1.12 per share, which was a penny above the Zacks Consensus Estimate of $1.11. Earnings were up 13.1% year-over-year, driven by effective price implementation and ongoing aggressive cost savings program. Net sales for the quarter were flat year-over-year declining marginally by 0.3% to $3.9 billion as unit volume increased 1.5% and pricing contributed 5.0%. This was partially offset by negative foreign exchange translation of 6.5%. Organic sales (excluding foreign exchange, acquisitions and divestitures) increased 7.0% in the quarter. North American sales increased 3.0% driven by 1.5% pricing and 5.0% unit volume growth, partially offset by 0.5% negative currency translations. In Latin America, sales grew 5.0% as unit volume increased 3.0% driven by solid gains in Venezuela which were partially offset by an 11.0% negative foreign exchange impact. In Europe/South Pacific, ...

This analysis is from John Derrick, U.S. Global Investors Director of Research. The market has rallied dramatically since the March 9 low, with the biggest beneficiary of this rally being low-quality companies. This intuitively makes sense, given that companies with the most troubled outlooks are the ones most likely to have a strong recovery when the dire outcomes predicted at the bottom of the crisis failed to transpire. Quality may have different meanings to different investors, but in a recent research piece, Citigroup ranked performance based on multiple definitions of quality. Samp;P earnings quality ranking, debt-to-capitalization ratio and return on equity were used as proxies for quality. The research universe was the small-cap Russell 2000 Index, but I believe broader market conclusions can be drawn as well. Based on Samp;P earnings quality rankings, companies with C or D (the two lowest categories) ratings returned about 55 percent over the past six months, while the ...

Two Sagging Economies… Two Laid-Back Banks

by Martin Denholm, Senior Editor

Anemic. Stagnant. Plodding.

Pick your favorite… it doesn’t matter. They all describe the state of the British and Eurozone economies.

Two weeks before the official third quarter U.K. GDP figure is released, the National Institute of Economic and Social Research (NIESR) delivered a somber verdict. The group says it actually didn’t grow at all, confounding those who said the economy started growing again.

Cue a fresh round of some good, old-fashioned British grumbling.

The culprit: a 2.5% fall in industrial production in August, as oil demand dropped. Still, neutral is better than reverse – a gear that Britain had driven in for 2009 up to that point, posting a 2.4% first-quarter slump and 0.6% second-quarter decline.

It’s not alone either. Its European neighbors are also backpedaling. The latest quarterly figure from Eurostat shows that the

...

The new CEO of TNK-BP will apparently be chosen by the end of the year, energy mogul Viktor Vekselberg has announced.  The Telegraph examines Total chief Christophe de Margerie's belief that oil prices may rocket back up to the $100 mark if further investment into oil exploration is not followed through.  According to Bloomberg, state-run monopoly Saudi Aramco says that it imagines little chance of pumping crude from idle fields in 2010 because demand for oil remains low.  Ukraine will offer 'absolute and unconditional guarantees' to restructure the debt of Naftogaz Ukrainy.  Greece is cooperating with Russia in the construction of the Burgas-Alexandroupolis oil pipeline and South Stream gas line, but with a predominant concern for its own interests, says Greek Prime Minister Costas Karamanlis, according to ITAR-TASS.   37 tenders for the Shtokman gas field ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday September 16, 2009

DrStockPick.com Stock Report!

**************************************************************

Power3 Medical Products Inc. CEO Interview: Helen R. Park

67 WALL STREET, New York - September 15, 2009 - The Wall Street Transcript has just published its Medical Research Services report offering a timely review of the sector to serious investors and industry executives. This 23 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Medical Device Research Services - Pharmaceutical Research Services - Diagnostics - Life Science Research Supplies

...

6Power3 Medical Products Inc. CEO Interview: Helen R. Park7 WALL STREET, New York - September 15, 2009 - The Wall Street Transcript has just published its Medical Research Services report offering a timely review of the sector to serious investors and industry executives. This 23 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Medical Device Research Services - Pharmaceutical Research Services - Diagnostics - Life Science Research Supplies - Biology R & D - Lab Services Business Model - International Economic Exposure - Effect of Recession on Sector Stocks - Top Stock Winners and Losers in Medical Research Services - Top Stock Winners and Losers in Medical Diagnostics

Companies include: Arrowhead Research (ARWR); Cleveland BioLabs (CBLI); IR BioSciences Holdings (IRBS); Power3 Medical Products (PWRM);

...

Access Pharmaceuticals Inc. develops and commercializes proprietary products for the treatment and care of cancer patients. The company today announced an agreement with commercial manufacturer Accupac Inc. to produce and distribute Access’ FDA-approved MuGard in the North American market.

MuGard is a mucoadhesive oral wound rinse for patients in radiation and chemotherapy that often-time develop mucositis, or the inflammation of mucous membranes along the lining of the digestive track, including the mouth. The company says the market for treating oral mucositis is estimated at $5 billion worldwide.

“Access is moving forward with the development of MuGard in North America,” Jeffrey B. Davis, Access’ president and CEO stated in the press release. “Establishing our relationship with Accupac, a leader in liquid contract manufacturing, is critical to our successful commercialization of MuGard. In addition, Access is currently evaluating potential eMarketing partners as well as potential co-promotion or other licensing opportunities.”

According to Access,

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

TBIO, Transgenomic Inc, TBIO.OB

Dr Stock Pick HOT News & Alerts!

Transgenomic and Power3 Medical Report Identification of Abnormal Serum

Proteins in Parkinson’s Disease

 

Tuesday September 8, 2009

************************************************************** Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson’s Disease

- On-line Publication of Biomarker Panel that Forms Basis for NuroPro(R)PD Diagnostic Test -

Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) announced recently the advance on-line publication of a clinical research paper entitled “Abnormal Serum Concentrations of Proteins in Parkinson’s Disease” in the scientific journal Biochemical and Biophysical Research Communications.

...

The following is an option strategy brought forth by IVolatility.com. I actually use their site to look at IV charts for options. The strategy they are suggesting is a Bullish Call Ratio Backspread and a Short Put on SLW, a silver mining company. The Silver Story In IVolatility Trading Digest™ Volume 9, Issue 32, The Season for Gold, dated August 17, 2009 and then again, in IVolatility Trading Digest™ Volume 9, Issue 33, Seasonal Gold 2.0, dated August 24, 2009 we suggested new positions in the precious metals sector using silver and gold. Since they have both quickly moved up to their previous resistance highs we offer some additional background information and another idea for a potential upside breakout. Gold (cash) at 994.40 is within 12.03 of testing the previous high at 1006.43 made on February 20, ...

PWRM, Power 3 Medical Products Inc, PWRM.OB

TBIO, Transgenomic Inc, TBIO.OB

Dr Stock Pick HOT News & Alerts!

Transgenomic and Power3 Medical Report Identification of Abnormal Serum

Proteins in Parkinson’s Disease

 

Friday September 4, 2009

************************************************************** Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson’s Disease

- On-line Publication of Biomarker Panel that Forms Basis for NuroPro(R)PD Diagnostic Test -

OMAHA, Neb. and HOUSTON, TX. /CRWENEWSWIRE/ — Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) announced the advance on-line publication of a clinical research paper entitled “Abnormal Serum Concentrations of Proteins in Parkinson’s Disease” in the scientific journal

...